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Recombinant Extracellular Matrix Protein Fragments
Support Human Embryonic Stem Cell Chondrogenesis
Aixin Cheng, MD, PhD,1,*,# Stuart A. Cain, PhD,1,* Pinyuan Tian, PhD,1 Andrew K. Baldwin, PhD,2
Paweena Uppanan, MSc, Cay M. Kielty, PhD,1 and Susan J. Kimber, PhD1
We previously developed a 14-day culture protocol under potentially GMP, chemically defined conditions, to
generate chondroprogenitors from human embryonic stem cells (hESCs). In vivo work has confirmed the cartilage
repair capacity of these cells in a nude rat osteochondral defectmodel. Aiming to enhance hESC-chondrogenesis, we
screened a range of extracellularmatrix (ECM)molecules for their ability to support differentiation of hESCs toward
chondrocytes.We identified two novel ECMprotein fragments that supported hESC-chondrogenesis: Fibronectin III
(fibronectin 7-14 protein fragments, including the RGD domain, syndecan-binding domain, and heparin-binding
domain) and fibrillin-1 (FBN1) fragment PF8 (encoded by exons 30–38, residues 1238–1605, which contains the
RGDmotif but not heparin-binding site). These twoprotein fragments support hESC-chondrogenesis comparedwith
the substrates routinely used previously (a mixture of fibronectin and gelatin) in our directed chondrogenic protocol.
We have identified recombinant fibronectin fragment (FN III) and FBNI fragment (PF8) as alternative coating
substrates to promote expression of genes known to regulate chondrocytes and code for chondrocyte ECM com-
ponents. These recombinant protein fragments are likely to have better batch to batch stability than full-length
molecules, especially where extracted from tissue/serum.
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Introduction
The articular cartilage covering of synovial jointsdisperses loading forces to the underlying subchondral
bone and provides a low-friction interface to facilitate joint
movement. After the closure of the growth plate, the articular
cartilage loses regenerative capacity due to the lack of blood
supply.1 Chondrocytes, the only cell type in cartilage, have a
low proliferation rate and produce all the extracellular matrix
(ECM) in the cartilage, mainly proteoglycans and other non-
collagenous molecules in adult cartilage, as turnover of the
type II collagen network is very slow.2 These characteristics
contribute to a lack of self-repair capacity in the event of
disease or trauma, when the integrity of cartilage is disrupted.3
Chondrocytes maintain healthy cartilage and are embedded
in the ECM, which contains a number of ECM components.
For example, collagen II and collagen XI fibers4–7 and pro-
teoglycans with 80% by weight of the tissue being fluid.8
Additional components include a collection of other molecules,
such as link protein, COMP, matrilins, decorin, and hyaluronic
acid, which act as bridging molecules and by binding to col-
lagens regulate the fibrillogenesis and assembly of the cartilage
network.9–12 Aggrecan is the major cartilage-specific pro-
teoglycan core protein to which glycosaminoglycan (GAG)
chains, predominantly chondroitin sulfate and keratan sulfate,
are attached forming a ternary complex with link protein and
hyaluronan,13–16 and aggrecan also binds to collagens.17
The pericellular matrix, the region adjacent to the chon-
drocytes, has a specialized composition, including collagens
and proteoglycans18,19 but also fibronectin (FN) and fi-
brillin1.20 Both interact with collagens, but their location
suggests that they are available for interaction with chon-
drocytes. As far as its role in collagen fibrillogenesis,21,22
FN has been shown to stimulate chondrocyte GAG forma-
tion in vitro23 and has well-established growth factor in-
teractions.24 Fibrillin-1 microfibrils are also deposited in the
cartilage ECM after adolescence and mutations cause skel-
etal abnormalities such as overgrowth of long bones.20
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b1-integrin adhesion molecules are the main ECM re-
ceptors for collagens and FN. The functional integrin dimers
formed by the alpha and beta transmembrane subunits reg-
ulate multiple biological processes such as proliferation,
migration, survival, and differentiation, including human
embryonic stem cells (hESCs).25,26 Collagens interact with
cells through a1-, a2-, a3-, and a10b1 receptors and a5b1
binds to FN.27 Specifically, a10b1 is required for normal
development of the cartilaginous growth plates,28 while
aVb6 is a receptor for fibrillin-129 and contains TGFb-1-
binding protein-like modules.30
We previously reported a directed differentiation protocol
(DDP) for hESCs, which mimics the natural development pro-
cess toward hyaline cartilage to generate chondrogenic cells.31
This protocol exploits the feeder-free and serum-free culture
system we developed to provide potential GMP conditions for
the growth and expansion of hESCs.26 We have shown that
hESC-chondrocytes can generate hyaline-like cartilage repair in
a nude rat osteochondral-defect model.32 Previously, cells have
been differentiated on plasmaFN in combinationwith gelatin. In
this study, we used this chemically defined chondrogenic dif-
ferentiation protocol to screen an array of recombinant ECM
molecules and protein fragments, including some found in car-
tilage, for support of hESC- chondrogenesis. We found FN and
fibrillin-1 recombinant fragments support hESC-chondrogenesis
in a manner equivalent to full-length FN.
Methods
Generation and purification of ECM peptide
All noncommercial protein fragments were expressed in
mammalian 293-EBNA cells and modified with either N or C
terminal His-tags. FN fragment FN III (residues 1176-2082
PLS..KKT) was cloned from RNA extracted from ARPE-19
cells and was modified with an N-terminal His6 tag (Fig. 1A).
Full-length human FN was cloned from mesenchymal stromal
cell (MSC) RNA and had a sequence matching Homo sapiens
fibronectin 1 (FN1), transcript variant X9 (XM_005246406.1).
This variant contains all FN domains apart from domain EDB
(Fig. 1A). The native FN signal sequence was replaced by the
BM40 signal peptide and a His6 tag. Recombinant human
fibrillin-1 fragments (PF1,PF2,PF8,PF9,PF17-1) andfibrillin-2
fragment (PF17-2) were modified with an N-terminal His6
tag.33–35 (Fig. 1B).ADAMTS6 full length is encodedby residues
22-1117, andADAMTS6C-terminal region starts at the 1st TSR
domain and is encoded by residues 558-1117modified,with aC-
terminalHis6 andV5 tag.36 Syndecan-4 ectodomain encoded by
residues 19-143 (ESI..IFE)36 and syndecan 2 ectodomain en-
coded by residues 19-141 (ESR..LFK) were expressed with a
C-terminal His10 tag. LTBP-1 was expressed with a C-terminal
His6 tag.37 Agrin fragments were cloned from RNA extracted
from ARPE-19 cells, Agrin K6-SEA (residues 535-1252) and
Agrin ST2-LGL3 (residues 1304-2064) were modified with an
N-terminal His6 tag. All proteins were purified using im-
mobilized metal ion affinity chromatography (IMAC) (HisTrap
FF GE Healthcare), under high salt conditions (0.5M NaCl).
Fibrillin-1, syndecan-4, and LTBP-1 fragments were further
purified using size-exclusion chromatography (Superdex 200 or
Superose 6, GEHealthcare). Purity of recombinant proteins was
analyzed using SDS-PAGE with Coomassie blue, and protein
concentrations were calculated using BCA Protein Assay
(Pierce) (Fig. 1C). Full amino acid sequences and expected
molecular masses of recombinant protein fragments FN III and
PF8, and recombinant full-length FN are shown in Supplemen-
tary Figure S1 (Supplementary Data are available online at
www.liebertpub.com/tea).
Preparation of ECM matrix assay plates
A 96-well plate coated with ECM molecules containing, in
duplicate, a range of concentrations (1, 10, 25mg/mL) fragments
of fibrillin-1, fibrillin-2, and agrin as well as cellular and plasma
FN was created as previously described.38 The plate also con-
tained single concentration of the following ECM proteins:
LTBP-1 C-terminal fragment, MAGP-1, syndecan-2 extracel-
lular domain, syndecan-4 extracellular domain, and fibulin4.
ECMproteins diluted in 80mLPBSwere incubated overnight on
96-well clear black plates (Greiner #655090) at 4C. The su-
pernatant was removed, and wells were blocked by the addition
of 10mg/mLbovine serumalbumin (BSA) for 1 h.BSAsolution
was removed, and the plates were stored at -80C before use.
BSA-coated and uncoated tissue culture plate (TCP) wells were
used as controls (Supplementary Table S1).
Quantification of adhered ECM proteins
To compare the relative quantities of absorbed protein
fragments on the tissue culture plastic surface, a modified
BCA protein assay was performed (Pierce BCA Protein
Assay Kit, 23225). Protein fragments were incubated on 96-
well tissue culture plastic plates in triplicate overnight at
concentrations of 5, 10, and 25 mg/mL. The plates were then
washed with PBS, before the absorbed protein was re-
solubilized from the surface using 50 mL of 4M Guanadine-
HCL for 1 h. Two hundred microliters of BCA working
reagent was then added and left to develop for 20min. Ab-
sorbance was measured at 570 nm, and background absor-
bance was subtracted (PBS only) (Supplementary Fig. S2).
Cell culture and directed chondrogenic differentiation
MAN6 and MAN7 cells were cultured, as previously
described.39 In brief, hESCs were cultured on mitomycin C-
inactivated mouse embryonic fibroblasts (iMEFs) in hESC-
medium. For feeder-free culture, cells were lifted from the
iMEF layers with TrypLE, (Thermo Fisher Scientific) and
plated onto plasma FN-coated (Millipore, lot 2594323,
2854203) (Supplementary Fig. S3) tissue culture flasks with
mTeSR1 medium (STEMCELL technology).26 The hESCs
were differentiated with sequential addition of growth factors,
as previously described.39 In brief, Wnt3a, Activin-A, and
BMP2 were applied to differentiate hESCs to primitive
streak–mesendoderm (day 1–3), followed by addition of
BMP4, follistatin, and GDF5 to differentiate to mesoderm
(day 4–8), finally, GDF5 with FGF2 was used to direct
chondrogenesis (day 9–14).
Screen novel ECM molecules/protein fragments
supporting hESCs chondrogenesis
hESCs undergoing chondrogenic directed differentiation
were seeded onto 96-well TCPs coated with a range of ECM
proteins or protein fragments at day 8 of the protocol as
3 · 104 cells/cm2. Cells were further cultured in chondro-
genic medium as described.32 On day 14 of the protocol,
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cells were fixed using 4% paraformaldehyde followed by
Safranin O staining (0.1% Safranin O, 5min).
Gene expression analysis
Total RNA was extracted using an RNeasy Kit (Qiagen)
and DNA removed using Ambion DNase I (Thermo Sci-
entific). Total RNA was reverse transcribed using M-MLV
reverse transcriptase (Promega). Expression of candidate
genes was determined using SYBR Green PCR Master Mix
(Applied Biosystems) with a CFX96/384 Touch Real-Time
PCR Detection System (Bio-Rad) using gene-specific oligo-
nucleotide primers (Supplementary Table S2). Expression
levels were normalized to K KGAPDH and calculated using
FIG. 1. Schematic diagram of protein fragments. (A) schematic diagram of the domain structure of full-length human
fibronectin (FN FL) and fibronectin type III 7 to 14 (FN III) fragment, which contains the RGD-cell binding site and the heparin
binding site. (B) domain organization of the recombinant fibrillin-1 fragment PF8 compared with full-length fibrillin-1. (C) SDS-
PAGE of full-length human fibronectin (FN FL), FN III 7-14 fragment, and fibrillin-1 fragment PF8 run under nonreducing and
reducing conditions. Full amino acid sequences and expected molecular masses of FN III, PF8, and recombinant full-length FN
are shown in the Supplementary Figure S1. Color images available online at www.liebertpub.com/tea
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the 2-DCt method. At least three independent differentiation
experiments were performed.
Flow cytometry
Single-cell suspensions were fixed in ice-cold methanol
(10min at -20C) and permeabilized by incubation with 1%
BSA, 0.5% triton-X-100 in PBS for 15min. Cells were in-
cubated with primary antibody (Rabbit mAb anti-SOX9,
Cell-Signaling Technology 94794; rabbit anti-Collagen II,
10 mg/mL, Novus NB100-91715) diluted in ice-cold block-
ing buffer (1% BSA in PBS) overnight at 4C followed by
appropriate secondary antibodies. Flow cytometry was
conducted using a BD Biosciences Fortessa, and the soft-
ware Diva gating was used for analysis. FSC-H plotted
against FSC-A and a gate drawn around the single cells.
This gate was applied to a plot of FSC-A against SSC-A,
and then, another gate was drawn around the cells, exclud-
ing the debris. The combination of these two gates was
applied to the histogram of the fluorescence measurement.
Cell lysate and western blotting
Cells were washed with cold PBS and lysed in RIPA
buffer (Thermo Fisher Scientific 89900) with protease in-
hibitor cocktail (Roche, 05892970001) for 10min on ice,
followed by centrifugation at 14,000 g at 4C for 15min.
The supernatant was saved, 20mg of protein was resolved by
10% SDS-PAGE gel electrophoresis and transferred to a
PVDF membrane blocked with 5% low-fat milk in TBST
for 1hr followed by primary antibodies (mouse anti-SOX9,
1 mg/mL, Abcam 76997; rabbit anti- Collagen II, 10 mg/mL,
Novus NB100-91715). The membrane was washed three
times with PBST and incubated in IRDye 800CM (LI-COR)
secondary antibody for 1 h at room temperature. It was
washed with PBST and scanned with the Odyssey CLx
Imaging System.
FIG. 2. Screening ECM molecules/peptides supporting hESC-chondrogenesis. On day 8 of DDP, 5 · 104 cells/cm2 were
seeded on 96-well plates coated with a variety of ECM molecules and further cultured for 6 days in chondrogenic medium.
On day 14, cells were fixed and stained with Safranin O (A), (for substrate abbreviations shown in Fig. 2A see Supple-
mentary Table S1), and the staining intensity was quantified with ImageJ (B). (C) Recombinant full-length fibronectin (Fn-
full), fibronectin fragment (FN III), fibrillin-1 fragment PF8, and plasma fibronectin (pFN) were plated at increasing
concentrations onto a 96-well plate (n = 4). Day 8 DDP chondroprogenitors were seeded and cultured until day 14, then
stained with Safranin O. The Area of Safranin O staining was quantified and plotted against concentration (D). Nonlinear
regression was performed using GraphPad Prism using [Agonist] versus response–Variable slope equation parameters.
DDP, directed differentiation protocol; ECM, extracellular matrix; hESC, human embryonic stem cell. Asterisks indicate
P values where *P £ 0.05; **P £ 0.01; ***P£ 0.001. Color images available online at www.liebertpub.com/tea
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Phalloidin staining
Cells cultured on different coating substrates were fixed
using 4% paraformaldehyde for 10min at room temperature,
then quenched and permeabilized, using 0.2M Glycine 0.5%
Triton x-100. Phalloidin–Atto 565 (Sigma, 94072) staining
was performed for 20min following the manufacturer’s in-
structions and then washed with PBS followed by nuclear
staining with DAPI (Thermo Scientific D1306) for 5min.
Images on six-well plates collected on a Leica TCS SP5
AOBS upright confocal using a 20· /0.50 HCX Apo L dip-
ping objective. Images on 96-well plates were collected using
CellInsight CX5 High-Content Screening Platform (Ther-
mo Fisher Scientific). Images were then processed and ana-
lyzed using Fiji ImageJ (http://imagej.net/Fiji/Downloads).
The area covered by the cells for each field of view was
calculated by adjusting the threshold to include only the
phalloidin stained cells; this gives an indication of the number
of cells attached and the amount of cell spreading and was
expressed as a% of the total image area. To quantitate the cell
area, phalloidin- and DAPI-stained images were processed
using CellProfiler V2.2.40 A pipeline was used that identified
the positions of the DAPI-stained nuclei, this information was
used to identify individual cells on the phalloidin-stained
images. The MeasureObjectSizeShape module then calcu-
lated cell area and morphology information.
Statistics
Data are shown as the mean – SEM. An unpaired t test for
data from two groups or one-way ANOVA for data from
groups of three or more was used to compare data. p values
<0.05 were considered to be significant.
Results
Screening of ECM proteins/protein fragments
supporting hESC-chondrogenesis
To screen ECM components that support hESC-
chondrogenesis, a range of ECMproteins and protein fragments
was coatedonto96-wellTCPs (Fig. 2, SupplementaryTableS1).
The plates were initially tested for attachment of human MSCs,
to ensure sufficient functional protein coating,MSCswere found
to adhere and cover a significantly larger cell area, on wells
containing FN (cellular and plasma) and on the fibrillin-1 frag-
ments containing the RGD motif (PF17 and PF8) (Supplemen-
tary Fig. S4) than on other substrates.An identical platewas then
used to screen hESC chondroprogenitors starting at day 8 of the
DDP. Cells were seeded at 5· 104 cells/cm2 and cultured in
chondrogenicmedium(containingBMP2,GDF5, andFGF2) for
6 days with medium changed daily. On day 14, cells were fixed
and stained with Safranin O to identify GAG formation indica-
tive of chondrogenesis (Fig. 2A). The relative intensity of Sa-
franin O staining was quantified across the plate using ImageJ
(Fig. 2B).
Full-length FN and PF8 (Fig. 1) reproducibly supported
generation of Safranin O-positive chondrogenic cells, as did
FN fragment FNIII (for structure refer to Fig. 1A) tested sep-
arately. We therefore decided to focus on these three molecules
for testing further their ability to support hESCs chondrogen-
esis. To identify the optimal concentration of substrate, in-
creasing concentrations of FN-full, FNIII, PF8, and plasma
FN were coated onto a 96-well plate. Day 8 hESC chondro-
progenitors were cultured until day 14, as above mentioned,
and stained with Safranin O (Fig. 2C). FN full, FNIII, and PF8
all reach Safranin O saturation at 10mg/mL, and so, this con-
centration was chosen for future experiments. The EC50 for
FIG. 3. Recombinant ECM supporting pluripotency and hESCs chondrogenesis. Recombinant full-length FN (rFN), FN
fragment (FNIII), and Fibrillin 1 fragment PF8were tested for supporting pluripotency ofMAN7cells alongwith plasma FN (pFN)
and vitronectin (Vitro). Recombinant FN full length and PF8 maintained pluripotency of MAN7 hESCs after 2 passages
(A). Fibronectin rFN,FNIII, andPF8were comparedwith amixture of plasmaFNandgelatin for supporting hESC-chondrogenesis
inMAN6 andMAN7 cell lines; qRT-PCRwas used to quantify chondrogenicmarker genes (B). Three runs for each cell lines were
performed and representative results are shown. Asterisks indicate P values where *P£ 0.05; **P£ 0.01; NS, non significant.
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saturation were FNII 1.3–0.04mg/mL, PF8 4.6–0.3mg/Ml,
and FN full 7.1–0.2mg/mL. Plasma FN alone did not support
chondrogenic staining in these experiments, and so, Gelatin/
Plasma FN mixture (Gel/FN) was used for further experiments.
Support for hESC-chondrogenesis by identified
ECM molecules
We then tested whether these three substrates could support
the culture of the starting hESCs and found that recombinant
full-length FN and PF8 support cell adhesion, culture expan-
sion, and maintenance of pluripotent MAN7 cells for two
passages, based on gene expression of pluripotency-associated
markers to the same extent as plasma FN or vitronectin, used
routinely in the laboratory. However, the FNIII fragment did
not even support hESC adhesion and was therefore excluded
from the hESC qRT-PCR analysis (Fig. 3A).
Next, we evaluated the hESC-chondrogenesis at the tran-
script level, by applying these substrates from day 8 to day 13
of our DDP with two lines, MAN6 and MAN7. Gene ex-
pression analysis showed that even though there was a small
variation between the different cell lines, PF8 and FNIII sup-
port hESC-chondrogenesis. Compared to 50:50 plasma FN and
gelatin used previously, on recombinant full-length FN, the
cells expressed equivalent SOX9, COL2A1, and COL11A1, but
higher ACAN and BGN. The protein fragments produced
similar results, although the increase in ACAN tended to be
lower, especially for MAN6 (Fig. 3B). However, RUNX2 ex-
press was also higher within cells cultured on full-length FN,
FNIII, and PF8 in this line. COL10A1 was not expressed to any
significant extent on any of the substrates (data not shown).
PF8 and FNIII support hESCs chondrogenesis through
maintaining SOX9 expression and GAG deposition
To explore further what underlies the support of PF8 and
FNIII protein fragments for hESC-chondrogenesis, we per-
formed western blot analysis for SOX9 protein in cells
cultured on the different substrates. We found that using
FNIII and PF8 as coating substrate, the expression level of
SOX9 was similar as that in the cells cultured on the mixture
of FN and gelatin (Fig. 4A, B). To further confirm the
protein levels for SOX9 and Collagen II in the cells cultured
on different substrates, we performed flow cytometry and
found that the expression level of SOX9 and collagen II
proteins was very similar in the cells cultured on all of
FNIII, PF8, and FN full length, confirming that they can
support hESCs chondrogenesis (Fig. 4C). More detailed
assessment and quantitation of Safranin O staining also in-
dicated that PF8, FNIII, and recombinant FN substrates have
the potential to promote equivalent or greater deposition of
GAG in differentiating chondrogenic cell aggregates com-
pared with the mixture of FN and gelatin. So, these sub-
strates appear to be able to support hESC-chondrocytes
ECM deposition (Fig. 5).
To check that there was no significant differences in the
amounts of recombinant protein on the tissue culture plastic
surface, when applied at 10 mg/mL for the four protein
substrates used, the absorption of each protein/protein
fragment was also quantified and no significant difference
was found, although the amount of protein from FN:gelatin
coatings was higher (Supplementary Fig. S2).
Effect of Different Coating Substrates
on the Assembly of F-actin
The chondrocyte cytoskeleton includes actin microfila-
ments, microtubules, and vimentin-intermediated filaments,41
and F-actin is cortical in location.42–45 This contrasts with its
location in fibroblastic cells and MSCs. We performed
FIG. 4. SOX9 protein level in hESCs during chon-
drogenesis on different coating substrates. MAN7 hESCs
were induced to undergo directed chondrogenic differenti-
ation, on day 8, different coating substrates were applied and
cells were cultured in chondrogenic medium to day 13. The
cell lysates were collected for western blotting to investigate
the expression of SOX9. Three independent runs were per-
formed and representative results are shown (A), and the
quantification of results from three runs are shown, nor-
malized to the ratio between SOX9 and GAPDH on day 0.
Statistical analysis was carried out using GraphPad Prism
using 1-way ANOVA and Tukey’s multiple comparison
test. Asterisks indicate p values where *p £ 0.05; **p £ 0.01.
(B). Flow cytometry analysis of SOX9 and collagen II level
in hESC- chondrogenic cells on different coating substrates.
MAN7 hESCs were induced to undergo directed chondro-
genic differentiation, on day 8, different coating substrates
were applied and cells were cultured in chondrogenic me-
dium to day 13. The cells were fixed and assessed by flow
cytometry using antibodies against SOX9 and Collagen II
and Alexa Fluor 488 secondary antibody (C). Color ima-
ges available online at www.liebertpub.com/tea
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phalloidin staining at 24 h after plating on Day 8, to inves-
tigate the distribution of f-actin and found that there was no
difference in the distribution of the f-actin on the different
substrates, both cortical actin and prominent stress fibers were
observed (Fig. 6A). On pFN and PF8, there were significantly
fewer cells attached even at higher concentrations of substrate
(Fig. 6B and Supplementary Fig. S5), and total cell area was
significantly lower for pFN and PF8 at the saturated con-
centration of 10mg/mL (Figs. 2C and 6C). On PF8 and pFN,
cells were less spread indicated by a lower average cell area
(Fig. 6D). By day 14, the cytoskeleton had altered, with a loss
of stress fibers, and an increase in cortical actin, although no
difference was seen between substrates (Fig. 6E). Collagen II
deposition could also be detected.
Discussion
In this study, we exploited our directed hESCs chondro-
genic differentiation protocol, mimicking development,39 to
screen a variety of 2D coating substrates. Our aim was to
find a substrate which could support chondrogenesis to the
same extent or better than the plasma FN/gelatin combina-
tion used previously. An ideal substrate could be produced
as a recombinant protein, in a cost-effective and reproduc-
ible manner avoiding batch-to-batch variation. We produced
an array of recombinant extracellular proteins and protein
fragments, including FN and fibrillin-1 fragments, which
were screened for hESC culture expansion and for genera-
tion of Safranin O positive cells in the DDP to generate
chondroprogenitors.
Compared with the previously used plasma FN and gel-
atin mixture, full-length recombinant FN, fibronectin frag-
ment (FNIII), and fibrillin-1 fragment (PF8) (Fig. 1.) could
all support adhesion and differentiation of the hESCs-
chondroprogenitors (Figs. 2 and 5). Adding FN to the medium
has been shown to promoter MSC chondrogenesis,46 and we
have shown that plasma FN supports the early stages of hESC-
chondrogenesis.32,39 In this study, we have demonstrated that
the FNIII fragment also promotes hESC-chondrogenesis in the
later stages of our 2D protocol. Fibrillin-1 (FBN1) is present
as a loose meshwork of fibers within cartilage matrix by 20
weeks of fetal gestation and then accumulates in the pericel-
lular matrix forming broad banded fibers by later adolescence.
Therefore, we propose that FBN1 may promote the maturation
of hESC chondroprogenitors.20 Both these protein fragments
contain RGD domains, which provide the binding motif for
cell surface receptor integrins.47 When other FBN fragments
that contained homologous EGF repeats, but non-RGD-
containing TB (TGFb-binding protein-like) domains were
used, they did not support cell attachment or chondrogenesis
in the initial screen for chondroprogenitors and MSC attach-
ment (Fig. 2 and Supplementary Fig. S4). Similar results for
cell attachment of induced pluripotent stem cells to only the
RGD-containing protein fragments were seen with an identi-
cal 96-well protein array.38
It has been shown that interaction of human articular
chondrocytes with RGD-containing protein fragments not
only initiates cell attachment but also promotes cell migra-
tion, proliferation, and maintenance of the chondrogenic
phenotype.48 So the RGD domain in FNIII and PF8 may
function beyond mere adhesion in supporting hESCs chon-
drogenesis. Indeed, chondrocyte attachment to FN occurs
through expression of the major integrin receptor for FN,
a5b1 which interacts with the RGD domain. Notably, b1
mediated ECM interaction is reduced in osteoarthritis.49–51
It has been suggested that FN–integrin interaction may play
a role in chondrocyte survival and retention in the cartilage
niche.51 Enrichment of the pericellular matrix with FN and
its integrin engagement could also contribute to the me-
chanosensing and mechanoregulation of the chondrocyte.18
Previously, we used plasma FN as coating substrates in our
differentiation protocol and the batch variation sometimes
FIG. 5. Safranin O staining for hESC-chondrogenic cells on different coating substrates. MAN7 hESCs induced to
undergo directed chondrogenic differentiation in 12-well plates, on day 8, different coating substrates were applied and cells
were cultured in chondrogenic medium to day 13. The cells were fixed and stained with Safranin O, whole plate images
were taken (A), and cells were then observed under the microscope (B). Three runs were performed and representative
images are shown. Scale bar: 100mm. Color images available online at www.liebertpub.com/tea
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hindered the reproducibility of the differentiation protocol. The
recombinant FN and fibrillin-1 fragment provide more reliable
coating substrates for hESCs, which can in future be made
under GMP conditions for translational application. Despite
some slight variation between the two lines tested in the ex-
pression of SOX9, collagen II, and collagen XI, the expression
of aggrecan and biglycan transcripts were enhanced by using
FNIII and PF8 (Fig. 3). It has been shown that biglycan in-
teracts strongly with collagen type II, but not with type I
in vitro.52 The enhanced expression of aggrecan and biglycan
may indicate that FNIII and PF8 have the capacity to promote
cartilage ECM production. The strong Safranin O staining also
indicates that FNIII and full-length FN promoted the deposi-
tion of GAGs during hESC-chondrogenesis compared with the
mixture of plasma FN and gelatin, while plasma FN only
supported chondrogenesis in a variable manner. So the tran-
sition from FN and gelatin to FNIII or PF8 may be beneficial
to promote ECM deposition as well as synthesis.
FIG. 6. Imaging of the actin cytoskeleton. Recombinant full-length fibronectin (FN-full), fibronectin fragment (FN III),
fibrillin-1 fragment PF8, and plasma fibronectin (pFN) were incubated at increasing concentrations on a 96-well plate
(n = 4). Day 8 DDP chondroprogenitors were seeded and cultured for 24 h. (A) Adherent cells were visualized with
phalloidin and DAPI stains, insert contains expanded region. Images are from 10 mg/mL of substrate. Scale bar: 100mm. (B)
The average area of phalloidin staining per field of view for increasing concentrations of substrate. (C) The average area of
phalloidin staining per field of view and (D) average cell area at 10 mg/mL of substrate were calculated using ImageJ and
CellProfiler, respectively. A montage of the images taken and CellProfiler cell identification is shown in Supplementary
Figure S5. Statistical analysis was carried out using GraphPad Prism using 1-way ANOVA and Tukey’s multiple com-
parison test. Asterisks indicate p values, where *p£ 0.05; **p £ 0.01; ***p £ 0.001; ****p £ 0.0001. (E) Day 8 DDP
chondroprogenitors were seeded onto different substrates on six-well plates. Day 14 cells were visualized by confocal
microscopy using phalloidin (red) and DAPI (Blue) stains. Collagen II (green) was visualized using a mouse anticollagen II
antibody (2B1.5, ab185430; Abcam). Insert contains expanded region. Scale bar: 100mm. Color images available online at
www.liebertpub.com/tea
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SOX9 is the master transcription factor regulating chon-
drogenesis53; if protein fragments can promote the expres-
sion of this transcription factor, there is a strong likelihood
of their supporting chondrogenesis. Actin polymerization
and filament formation has been shown to negatively regu-
late the transcriptional activity of SOX9 and induce chon-
drocyte dedifferentiation, in which chondrocytes lose
chondrogenic gene expression and cell morphology changes
from round to fibroblast-like.54 As FN regulates assembly of
actin filaments in fibroblasts through the RGD domain and
C-terminal heparin-binding region,55 we also investigated
the effect of different substrates on f-actin assembly. After
24 h seeding on different coating substrates from Day 8,
staining with phalloidin revealed significant cell spreading,
but interestingly, fewer hESC-chondrogenic cells attached
on PF8 and these were less spread, with a smaller cell area
(Fig. 6). However, by day 14, the differences in the chon-
drogenic cell staining using Safranin O was not as pro-
minent. Moreover, by day 14, imaging of the actin
cytoskeleton revealed that it had been remodeled to be
mainly cortical in distribution (Fig. 6). As the relaxation of
f-actin can potentially restrict the spreading of hESC-
chondrogenic cells, it could be beneficial to promoting
their differentiation as shown for chondrocytes.56
When chondrocytes become elongated with flattened and
elongated actin stress fibers, they decrease synthesis of type
II collagen and aggrecan, but increase type I collagen syn-
thesis, thus, dedifferentiating to a fibroblast-like pheno-
type.57 On the contrary, if chondrocytes are induced to
become rounded, the chondrocyte phenotype is rescued.56
Taking this together, we propose that FNIII and PF8 may
contribute to the promotion of hESC-chondrogenesis
through triggering or allowing the remodeling of actin as-
sembly to that more conducive to chondrogenesis.
Our study has demonstrated that the recombinant ECM
molecules, FN and its fragment FN III as well as the
fibrillin-1 fragment PF8 can replace the mixture of plasma
FN and gelatin as optimal coating substrates for hESC-
chondrogenesis. As the quality of these recombinant ECM
molecules is more reliable than plasma FN, their use will
increase the reproducibility of hESC chondrogenic differ-
entiation. Since these substrates can be made under GMP
conditions, they are well placed to be used for clinical ap-
plication of chondrogenic cells for transplantation. Fur-
thermore, the facilitation of cortical actin distribution by
these substrates is conducive with a chondrocyte phenotype,
and the role of particular protein fragments in this warrants
further investigation. Better understanding of the role of the
matrix in mesenchymal condensation, formation of the en-
dochondral skeleton, and chondrocyte development to form
the permanent cartilage may bring advantages in dissecting
the causes of aberrant cartilage and bone formation in
chondrodysplasias as well as in generation of chondrocytes
for cell therapy.
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